Psilocybin mushroom

'From Magic Mushrooms to Big Pharma' – a college course explores nature's medicine cabinet and different ways of healing

Retrieved on: 
Saturday, June 10, 2023

Title of course:

Key Points: 
  • Title of course:
    “From Magic Mushrooms to Big Pharma”
    What prompted the idea for the course?
  • The course looks at how different peoples and cultures use nature-based medicines to heal themselves.
  • Some of us rely on Western medicine, others pray, yet others turn to Indigenous or traditional ways of healing that are rooted in nature.
  • Over the course of the semester, students begin to recognize that there is no one right way of healing.

Kaya, One of the Largest Vertical Cannabis Companies in the Caribbean, Introduces Psychedelic Mushroom Chocolate; Updates on Jamaica’s Legal Psilocybin Market

Retrieved on: 
Wednesday, May 10, 2023

Kaya will sell its Psychedelic Mushroom Chocolate in a flat bar that contains 1000mg of psilocybin per bar that can be broken into four equal-sized pieces containing 250mg of psilocybin per square.

Key Points: 
  • Kaya will sell its Psychedelic Mushroom Chocolate in a flat bar that contains 1000mg of psilocybin per bar that can be broken into four equal-sized pieces containing 250mg of psilocybin per square.
  • Kaya's Psychedelic Mushroom Chocolate bar will consist of individually wrapped Jamaican-sourced, handmade dark, and white chocolate.
  • Psilocybin, a naturally occurring psychedelic compound found in certain mushrooms, has gained increasing attention for its potential to treat various mental health conditions, including depression, anxiety, and addiction.
  • According to a recent article in Psychology today, psychedelic mushroom chocolate was first used by the Aztecs in a practice called "cacahua-xochitl," which translates as "chocolate-mushrooms."

Nootropic Mushrooms for Wellness Are on the Rise

Retrieved on: 
Friday, July 30, 2021

Sun and Psilo is taking the most beneficial mushrooms, and making them palatable in tinctures, capsules and soon to be gummies.

Key Points: 
  • Sun and Psilo is taking the most beneficial mushrooms, and making them palatable in tinctures, capsules and soon to be gummies.
  • The studies *on the cognitive benefits of lion's mane mushrooms are phenomenal, and when taken in conjunction with psilocybin mushrooms, it's the perfect pair."
  • In May of 2019, Denver, Colorado passed a ballot measure decriminalizing psilocybin mushrooms, more commonly known as magic mushrooms, or simply shrooms.
  • While Sun and Psilo eventually plans to enter the legal psychedelics space, the current focus is nootropic and supplemental mushrooms, including lions mane, chaga , cordyceps and more.

MCOA Subsidiary cDistro Signs Distribution Agreement with Silo Wellness and Marley One Functional Mushrooms 

Retrieved on: 
Tuesday, June 29, 2021

Silo Wellness, a leading global psychedelics company, chosecDistro as one of its first distributors to launch Marley One, the first global functional and psychedelic mushroom consumer brand.

Key Points: 
  • Silo Wellness, a leading global psychedelics company, chosecDistro as one of its first distributors to launch Marley One, the first global functional and psychedelic mushroom consumer brand.
  • Silo has also announced that it intends to launch a psychedelic mushroom product line under the Marley name later this year, to be followed by additional functional mushroom products including gummies, capsules and cosmetics.
  • TheMarley family name is an iconic part of our history and were thrilled tobringthese exciting new products into our fast growing distribution portfolio.
  • We have already commenced our marketing efforts tointroduce and distribute Marley One, in collaboration withSilo Wellness and theBob Marley Family.

Lobe Sciences Enters into LOI with Core One Labs to Form a Joint Venture for the Clinical Development of Biosynthetic Psilocybin

Retrieved on: 
Wednesday, April 28, 2021

"A joint venture is the logical next step for us as it has the potential to provide cGMP grade psilocybin for use in clinical studies we plan to initiate in the future.

Key Points: 
  • "A joint venture is the logical next step for us as it has the potential to provide cGMP grade psilocybin for use in clinical studies we plan to initiate in the future.
  • "\nThe Agreement proposes that Core One Labs would develop and manage the cGMP production and delivery of biosynthetic psilocybin and Lobe would be responsible for the clinical development, and commercialization of the product(s).
  • Vocan Biotechnologies Inc. ("Vocan"), a wholly-owned subsidiary of Core One Labs, would produce the biosynthetic psilocybin and other psychedelic compounds to be used.
  • Vocan has identified a patentable method of producing psilocybin, the active ingredient in psychotropic mushrooms.\nThe structure and terms of the Joint Venture remains subject to negotiation between the parties.

Why Companies Are Betting Big On Psychedelic Drugs To Treat Mental Health Epidemic

Retrieved on: 
Wednesday, April 28, 2021

Once dismissed as a "party drug" for its hallucinogenic effects, ketamine is emerging as a novel alternative treatment for depression.

Key Points: 
  • Once dismissed as a "party drug" for its hallucinogenic effects, ketamine is emerging as a novel alternative treatment for depression.
  • For most, psychedelic drugs conjure up images of the 1960\'s, hippies tripping out on LSD or magic mushrooms.
  • However, early studies are finding that psilocybin the active agent in magic mushrooms could treat addiction, depression, anxiety and mental health conditions like post-traumatic stress disorder (PTSD).
  • You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements.

Why Companies Are Betting Big On Psychedelic Drugs To Treat Mental Health Epidemic

Retrieved on: 
Wednesday, April 28, 2021

Once dismissed as a "party drug" for its hallucinogenic effects, ketamine is emerging as a novel alternative treatment for depression.

Key Points: 
  • Once dismissed as a "party drug" for its hallucinogenic effects, ketamine is emerging as a novel alternative treatment for depression.
  • For most, psychedelic drugs conjure up images of the 1960\'s, hippies tripping out on LSD or magic mushrooms.
  • However, early studies are finding that psilocybin the active agent in magic mushrooms could treat addiction, depression, anxiety and mental health conditions like post-traumatic stress disorder (PTSD).
  • You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements.

Why Mainstream Mental-Health Care is Embracing Psilocybin - Alternative Active Substances

Retrieved on: 
Wednesday, March 31, 2021

While the study of psychedelics as medicine, all across the globe, is inching toward the mainstream, it still remains somewhat controversial.

Key Points: 
  • While the study of psychedelics as medicine, all across the globe, is inching toward the mainstream, it still remains somewhat controversial.
  • A recent article on WIRED (UK) projected that Psychedelic medicine will begin to cross over into the mental health mainstream in 2021.
  • "In both Europe and the US, medicines regulators have eased restrictions on using MDMA to treat post-traumatic disorder (PTSD), and on psilocybin the active substance in magic mushrooms to treat depression.
  • In the UK, London-based mental-health care company COMPASS Pathways has raised more than $115m to fund its efforts and bring to market a psilocybin treatment for depression.

Why Mainstream Mental-Health Care is Embracing Psilocybin - Alternative Active Substances

Retrieved on: 
Wednesday, March 31, 2021

While the study of psychedelics as medicine, all across the globe, is inching toward the mainstream, it still remains somewhat controversial.

Key Points: 
  • While the study of psychedelics as medicine, all across the globe, is inching toward the mainstream, it still remains somewhat controversial.
  • A recent article on WIRED (UK) projected that Psychedelic medicine will begin to cross over into the mental health mainstream in 2021.
  • "In both Europe and the US, medicines regulators have eased restrictions on using MDMA to treat post-traumatic disorder (PTSD), and on psilocybin the active substance in magic mushrooms to treat depression.
  • In the UK, London-based mental-health care company COMPASS Pathways has raised more than $115m to fund its efforts and bring to market a psilocybin treatment for depression.

Medical Breakthroughs Propel Psilocybin Closer to Legalization

Retrieved on: 
Monday, March 1, 2021

For example, earlier in 2019, Colorado became the first state to decriminalize magic mushrooms (mushrooms containing psilocybin).

Key Points: 
  • For example, earlier in 2019, Colorado became the first state to decriminalize magic mushrooms (mushrooms containing psilocybin).
  • Psilocybin is a naturally occurring psychedelic compound produced by more than 200 species of mushrooms, collectively known as psilocybin mushrooms.
  • 'Mindleap's software patents will strengthen our intellectual property portfolio overall which now totals 8 patent filings currently in process.'
  • The Mindleap platform brings convenience, improves access to treatments and can lead to more personal breakthroughs.